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Accumulating evidence indicates that the protective
effect of mesenchymal stem cells in models of tissue
injury is related to the endocrine/paracrine release of
factors. The delivery of growth factors, cytokines,
prostaglandins, enzymes or extracellular vesicles from
mesenchymal stem cells to target cells may induce
cell reprogramming and de novo expression of factors
involved in tissue proliferation and repair. A recent
paper showed that Wharton jelly-derived
mesenchymal stem cells interact with injured renal
tubular epithelial cells, inducing the expression of
native and foreign hepatocyte growth factor
necessary for renal repair and fibrogenesis inhibition.
The genetic exchange between resident and
mesenchymal stem cells, probably mediated through
microvesicles, therefore appears instrumental in
mesenchymal stem cell therapeutic effects.cell-to-cell communication that may re-program targetIn virtue of their anti-inflammatory and tissue-regenerating
properties, mesenchymal stem cells (MSCs) appear a prom-
ising approach for the treatment of renal tissue injury. The
possible mechanisms involved are under deep investigation.
In this context, the paper published by Tao Du and
colleagues provides evidence that human Wharton jelly-
derived mesenchymal stem cells (WJ-MSCs) delay epi-
thelial–mesenchymal transition and alleviate renal fibrosis
in a model of renal ischemia and reperfusion injury in the
rat [1]. In the search for underlying mechanisms, the
authors identify the relevance of the hepatocyte growth
factor (HGF)/transforming growth factor beta 1 balance in this
process, HGF being able to inhibit epithelial–mesenchymal* Correspondence: benedetta.bussolati@unito.it
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© 2013 BioMed Central Ltd.transition and to block fibrogenesis [1]. Indeed, after
in vivo administration of WJ-MSCs, HGF gene expression
and protein release was upregulated in tubular epithelial
cells. Of interest, human HGF mRNA was also detected
by real-time PCR, indicating that WJ-MSCs induce in vivo
both native and foreign HGF expression in injured tubular
cells. Accordingly, conditioned medium produced by WJ-
MSCs induced in vitro HGF mRNA upregulation and pro-
tein release of both rat and human origin in hypoxic rat
tubular epithelial cells. These data indicate that human
HGF gene transcript, released by WJ-MSCs, is delivered
to tubular cells and then translated into protein. The ex-
planation proposed by the authors is that a genetic trans-
fer mediated by WJ-MSC-released microvesicles (MVs)
may support the tubular induction of human HGF in the
rat [1].
Accumulating data indicate that MVs released from
many cells target specific cells from other tissues. Indeed,
MVs have been recently described as new mediators of
cells through the active transfer of proteins, functional
mRNAs and miRNAs [2]. As a consequence of the active
genetic transfer, MVs derived from bone marrow (BM)
MSCs were shown to promote tissue regeneration in
different experimental animal models of renal injury. In
particular, therapeutic administration of a single dose of
MSC-derived MVs accelerated the morphological and
functional recovery in glycerol-induced acute kidney
injury and prevented lethality in cisplatin-induced acute
kidney injury [3-5]. In addition, administration of multiple
doses of BM MSC-derived MVs, at different time points
after injury, improved mice survival and prevented chronic
renal injury [4,5]. MSC-derived MVs also displayed protec-
tion against renal injury in the mouse model of 5/6 sub-
total nephrectomy, preventing renal fibrosis [6].
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tributed to RNA delivery, as inactivation of RNA dimin-
ishes their properties [3-5]. Reis and colleagues have also
recently reported that whole conditioned medium or
purified MVs from BM MSCs ameliorated gentamicin-
induced acute kidney injury, effects that were blunted
after incubation with RNase, confirming that the regen-
erative properties of MSCs were mediated by MV-
carried RNAs [7]. Although it is likely that single
mRNA, miRNA or protein act in concert to gain the
MSC therapeutic effect, the paper by Du and colleagues
identifies the genetic transfer of HGF to resident cells as
instrumental for inducing renal repair and for avoiding
fibrogenesis in renal ischemia–reperfusion injury [1]. In
parallel, a native HGF induction in tubular epithelial
cells induced by other factors was reported [1]. Another
recent study points out the involvement of insulin
growth factor 1-receptor mRNA transferred through BM
MSC-derived MVs in promoting the proliferation of
damaged proximal tubular cells [8].
The implication of MSC-derived MVs is considered a
general mechanism, as shown in other experimental
models such as myocardial ischemia–reperfusion injury
[9]. In addition, as shown by the paper from Du and col-
leagues [1], MSC types other than BM MSCs share this
communication property. The interaction of tissue-
localized MSCs and injured cells might also present
more complex dynamics. The microenvironment, pos-
sibly MVs or growth factors, released from injured cells
has been proposed to perhaps modify MSCs localized
into tissues, thus inducing a bidirectional mechanism to
promote tissue repair [10]. Strategies to mimic these
possible MSC modifications induced by the injured
microenvironment include MV collection by cells placed
under stress.
All together, these data show that the beneficial effects
of MSCs can be attributed, at least in part, to communi-
cation mechanisms involving MVs. During MSC therapy,
the delivery of proteins, mRNA and miRNA to tubular
epithelial cells may induce cell reprogramming and
de novo expression of factors involved in tissue prolifera-
tion and repair, such as HGF [1]. The modifications in
target cells appear to be stable and result in significant
functional effects. However, several issues still need to
be elucidated on the effects of MSCs in renal repair, in-
cluding the mechanisms of MV uptake and action and,
for a possible therapeutic use of MVs themselves, their
bio-distribution and dosage.
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